157 related articles for article (PubMed ID: 18184191)
1. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.
Katz LH; Fraser A; Gafter-Gvili A; Leibovici L; Tur-Kaspa R
J Viral Hepat; 2008 Feb; 15(2):89-102. PubMed ID: 18184191
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.
Li H; Zhang HM; Chen LF; Chen YQ; Chen L; Ren H; Hu HD
Clin Res Hepatol Gastroenterol; 2015 Feb; 39(1):80-92. PubMed ID: 25199680
[TBL] [Abstract][Full Text] [Related]
4. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Loomba R; Rowley A; Wesley R; Liang TJ; Hoofnagle JH; Pucino F; Csako G
Ann Intern Med; 2008 Apr; 148(7):519-28. PubMed ID: 18378948
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
[TBL] [Abstract][Full Text] [Related]
6. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
8. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
10. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
11. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
Katz LH; Paul M; Guy DG; Tur-Kaspa R
Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
14. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.
Ziakas PD; Karsaliakos P; Mylonakis E
Haematologica; 2009 Jul; 94(7):998-1005. PubMed ID: 19454492
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
[TBL] [Abstract][Full Text] [Related]
16. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
17. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
20. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
